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Background: Overexpression of HER2 is observed in 20 to 30% of breast carcinomas. The use of trastuzumab has
improved the treatment of these patients, especially when it is associated with docetaxel. To optimize the use of
this treatment, it seems important to select putative complete responders before treatment administration.
Methods: In this study, we analyzed by quantitative PCR the expression of 28 genes in HER2-overexpressing tumors
treated with trastuzumab + docetaxel-based chemotherapy. We then correlated their expression profile with those
of trastuzumab-sensitive and resistant cell lines to classify tumors as having a sensitive (pCR) or resistant (non-pCR)
profile. Finally, we used public datasets from the GEO website to validate the reduced gene-expression profile
obtained.
Results: We identified an 8-gene-expression combination that predicted the response to treatment with an accuracy
of 76%. Based on public microarray data, we showed that the expression profile was specific to first-line trastuzumab +
docetaxel-based treatment with an accuracy of 85%.
Conclusions: Our results showed that by profiling the expression of 8 genes it was possible to predict the response to
first-line trastuzumab + docetaxel-based chemotherapy. The use of cancer cell lines as the reference allowed a proper
fit with the specificity of different tissues, such as lung or gastric cancers, which could also be eligible to concomitant
HER2 inhibition by treatment with trastuzumab or tyrosine kinase inhibitors and docetaxel.
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Breast cancer is the leading cause of death by cancer in
women in industrialized countries. The amplification
and overexpression of human epidermal growth factor
receptor 2 (HER2) is observed in 20–30% of invasive breast
cancers. For locally-advanced, HER2-overexpressing breast
cancer, docetaxel + trastuzumab-based neoadjuvant chemo-
therapy has been shown to achieve promising efficacy, with
a good pathological complete response (pCR) rate, while
being well tolerated in women with stage II or III HER2-
positive breast cancer [1,2]. Women who achieve a pCR* Correspondence: rboidot@cgfl.fr
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unless otherwise stated.have significantly improved survival [3], but only 50% of pa-
tients with HER2-positive tumors treated with trastuzumab
have pCR.
In a previous study [4], we showed that a 28-gene signa-
ture dichotomized responses to trastuzumab + docetaxel-
based regimens. In the present study, we used real-time
quantitative PCR to analyze the expression of these 28
genes in 45 frozen HER2+++ tumors and 6 mammary
cancer cell lines that were sensitive or resistant to trastu-
zumab (Additional file 1). Next, we used public datasets
(GSE37946 [5], GSE22358 [6], and GSE42822 [7]) to test
the prediction capacity of the refined signature in different
treatment regimens.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Patients and samples
We retrospectively analyzed 45 frozen HER2+++ tumors
(Table 1). In addition, we also studied 34 FFPE HER2+++
tumors (Table 1). The study was conducted in accordance
with the Declaration of Helsinki and approved by an Eth-
ics Committee, the Comité Consultatif de Protection des
Personnes en Recherche Biomédicale de Bourgogne. Writ-
ten informed consent was obtained from all patients be-
fore enrollment. RNA was extracted from frozen samples
as described previously [4] and from FFPE samples with
the RNeasy FFPE kit (Qiagen) by following manufacturer’s
protocol.
Trastuzumab-sensitive cell lines BT474, HCC2218,
UACC-812, and resistant cell lines HCC1419, HCC1954,
and HCC1569 were obtained from ATCC and cultured
in accordance with the supplier’s instructions. The treat-
ment of cells before RNA extraction was identical to that
for patients’ tumors.
Gene expression analysis
The transcriptional expression of the 28 genes was stud-
ied by real-time quantitative PCR thanks to Taqman
Gene Expression Assays: PEX19 (Hs00267867), PSMD11
(Hs00160660), SENP8 (Hs00744981), PRKACA (Hs004
27274), CTNS (Hs00191849), NFE2L1 (Hs00231457),
PPP2CA (Hs00427259), SENP7 (Hs00221046), SYNCRIPTable 1 Demographic data of patients analyzed








Estrogen Receptors - 18 15
Estrogen Receptors + 27 19
Progesterone Receptors - 24 17





Not available 2 2
Tumour size
2-4 cm 23 18
>4 cm 7 5
Not available 15 11
Pathological response
pCR 18 12
non-pCR 27 22(Hs03044160), CEP89 (Hs01071366), SLC30A6 (Hs0021
5827), LAMA3 (Hs00165042), STX1A (Hs00270282),
GPR22 (Hs01127309), GRHL2 (Hs00227745), DERL1
(Hs00225583), FAM114A2 (Hs03837084), PITPNA (Hs0
0737576), CDC14A (Hs00185432), SLC35A4 (Hs003654
08), KIAA1549 (Hs00860114), LOC158402 (Hs003274
89), ZNF146 (Hs00173196), C5orf3 (Hs00218834),
WEE1 (Hs01119384), P2RX1 (Hs00175686), MFSD6




sion was calculated thanks to the 2-ΔCt method with 18S
expression used as the reference gene.
Public dataset study
The public dataset was downloaded from the Gene Ex-
pression Omnibus website. After the selection of genes of
interest, the data were log transformed when necessary.
Genes and arrays were median centered. Then, non-
supervised hierarchical clustering was performed by calcu-
lating Euclidian distances.
Statistical analysis was performed with Graph Pad
Prism Software or Statview 5.0 software.
Results
Expression profile predicting response to docetaxel +
transtuzumab-based neoadjuvant chemotherapy
In order to predict the response to treatment, we calcu-
lated the correlation coefficient of each tumor with each
cell line. The correlation coefficient nearest to 1 corre-
sponds to the prediction profile. As the tumor response
was known, we eliminated genes one by one until we ob-
tained the best prediction performances. This was
achieved (Table 2) with the association of the expression
of only 8 genes: CTNS, DERL-1, FAM114A2, KIAA1549,
P2RX1, PITPNA, PSMD11, and WEE1. As an example,




pCR 12 6 18
Non-pCR 5 22 27




Positive predictive value 17/18 94
Negative predictive value 28/27 104
Accuracy 34/45 76
Schmitt et al. BMC Cancer  (2015) 15:169 Page 3 of 6correlation between patient A’s tumor cells and the ref-
erence cell lines showed r = 0.93 with the sensitive
HCC2218 cells, whereas we obtained r = −0.36 with the
resistant HCC1419 cells, classifying it as a sensitive
tumor (Figure 1A). In contrast, patient B’s tumor cells
correlated positively with the resistant HCC1954 cell line
(r = 0.85) and negatively with the sensitive BT474 cells
(r = −0.25), classifying it as a resistant tumor (Figure 1B).Figure 1 Data obtained with the analysis of mRNA expression on tum
and a resistant (HCC1419) cell line for the expression of the 8 genes. The corr
with resistant cells, thus classifying it as a sensitive tumor. B. Correlation betw
cell line for the expression of the 8 genes. The correlation coefficient for this t
classifying it as a resistant tumor. C. Expression levels of the 8 genes in pCR and
different between pCR and non-pCR tumors. The p value was calculated with t
around the median value, which explains why higher values do not appear onAll correlation coefficients are presented in Additional
file 2. Surprisingly, the expression level of these 8 genes
individually was not significantly different between pCR
patients and non-pCR patients (Figure 1C), suggesting
that the combination of the expressions more than the
expression of each gene individually was responsible for
the prediction capacity. In parallel, we also studied corre-
sponding FFPE samples for 34 patients of our populationors. A. Correlation between a pCR tumor with a sensitive (HCC2218)
elation coefficient for this tumor was 0.93 with sensitive cells and −0.36
een a non-pCR tumor with a sensitive (BT474) and a resistant (HCC1954)
umor was −0.25 with sensitive cells and 0.85 with resistant cells, thus
non-pCR tumors. The expression level of each gene was not significantly
he non-parametric Mann and Whitney U test. Graphs represent a zoom
graphs. Median values are indicated by a red solid line.
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signature could also be assessed on FFPE samples, we
calculated correlation coefficients of each gene between
frozen and FFPE paired samples. Except for DERL-1
(r = −0.19), the 7 genes CTNS (r = 0.77), FAM114A2
(r = 0.19), KIAA1549 (r = 0.61), P2RX1 (r = 0.44), PITPNA
(r = 0.44), PSMD11 (r = 0.39), and WEE1 (r = 0.13) corre-
lated positively suggesting that paraffin treatment of sam-
ples did not alter the expression of the genes. The absence
of a positive correlation for DERL-1 expression between
frozen and FFPE samples could have been due to the
smaller number of FFPE samples.
The expression profile is specific to response to first-line
neoadjuvant docetaxel + trastuzumab-based
chemotherapy
To test the prediction capacity of the combined expression
of the 8 genes in different conditions, we used microarray
datasets available on the GEO website. We first correlated
the expression of our 8 genes with the expression of
ERBB2. The 8 genes correlated significantly and positively
with ERBB2 expression (Additional file 3). As our first gene
expression signature was obtained from tumors treated
with trastuzumab + docetaxel-based chemotherapy, we
tested the prediction in patients treated with first-line neo-
adjuvant - docetaxel-based regimen (GSE22358), first-line
neoadjuvant - trastuzumab monotherapy (GSE37946), or
first-line neoadjuvant - trastuzumab + docetaxel-basedFigure 2 Non-supervised hierarchical clustering obtained with public
not correctly distinguish between pCR and non-pCR tumors treated with a
with a trastuzumab monotherapy regimen. C. In contrast, pCR were disting
treated with a first-line neoadjuvant trastuzumab + docetaxel-based regime
2 response subgroups. D. The use of first-line neoadjuvant chemotherapy b
capacity of our profile. Green and red colors represent underexpression orchemotherapy (GSE22358). When the regimen con-
tained docetaxel without trastuzumab (Figure 2A) or
trastuzumab alone (Figure 2B), our profile was not able
to dichotomize tumor response. In contrast, the re-
sponse of patients treated with first-line trastuzumab +
docetaxel-based chemotherapy was well classified by
our profile (Figure 2C). Indeed, the accuracy of the
classification was 85% (23/27), with a sensitivity of 92%
(11/12) and a specificity of 80% (12/15). Finally, it ap-
peared that the profile was not usable for a second-line
neoadjuvant trastuzumab + docetaxel-based regimen, at
least after first-line neoadjuvant 5-fluorouracile + epiru-
bicin + cyclophosphamide (GSE42822) (Figure 2D). This
could be explained by modifications in tumor cell gene ex-
pression induced by the first treatment, which may have
influenced the subsequent response of tumor cells to do-
cetaxel + trastuzumab.
Discussion
Based on available public datasets, it appeared that the
combination of the expression of only 8 genes could
correctly dichotomize the response of HER2-positive ad-
vanced breast tumors to first-line trastuzumab + docetaxel-
based chemotherapy. The accuracy of prediction was
between 76% based on quantitative PCR data (Table 2) and
85% based on the GEO dataset. This is equivalent to the
prediction accuracy obtained with the analysis by Positron
Emission Tomography of the 18FDG uptake of tumorsdatasets. A. The combined expression of the profile genes did
docetaxel-based chemotherapy. B. The same observation was made
uished from non-pCR tumors (accuracy of 85%) when tumors were
n. The vertical red dashed line represents the separation between the
efore treatment with trastuzumab + docetaxel altered the prediction
overexpression centered on median array values, respectively.
Figure 3 Methodology for the prediction of pCR or non-pCR. Six cancer cell lines and tissue samples to analyze were treated in the same
way. After real time quantitative PCR analysis, correlation coefficients between samples and cell lines were calculated. The sample of interest was
classified as pCR if the higher coefficient was close to a sensitive cell line or as non-pCR if the higher coefficient was close to a resistant cell line.
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[8,9]. The gene expression method, however, has the ad-
vantages of a lower cost of analysis and a prediction avail-
able before the therapeutic decision.
The association of trastuzumab and docetaxel is also
used as an adjuvant treatment for operable breast cancer
[10], and in a small number of non-small-cell lung car-
cinomas [11]. In these cases, it could be interesting to
evaluate the ability of our profile to predict the efficacy
of adjuvant chemotherapy in breast cancer and the re-
sponse of non-operable NSCLC by using activated HER2
lung cancer cell lines as the reference to avoid tissue-
origin bias. Recently, HER2 overexpression was detected
in 16% of gastric cancers and was associated with a poor
prognosis [12]. As this sub-population of gastric cancer
patients could benefit from a trastuzumab + docetaxel-
based regimen [13], it would be interesting to assess the
prediction accuracy of our 8-gene expression profile in
this population. Equally, our profile could be tested for
the response prediction to a treatment with new HER2
tyrosine kinase inhibitors, which can be associated with
docetaxel [14], by using HER2 overexpressing gastric
cancer cell lines as the reference.
Conclusions
In conclusion, we showed that analysis of the transcriptional
expression of 8 genes present in frozen or FFPE tumors
could be used to dichotomize HER2+++ patients as poten-
tially sensitive or resistant to neoadjuvant trastuzumab +docetaxel based chemotherapy (Figure 3). The use of cancer
cell lines treated in exactly the same way as tumor cells en-
ables the easy and accurate classification of patients.
Additional files
Additional file 1: Validation of sensitivity and resistance of cancer
cell lines used as reference.
Additional file 2: Correlation coefficients obtained for each sample.
Additional file 3: Correlation coefficients between expression of the
8 genes and Erbb2.
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